Kailera Therapeutics

About Kailera Therapeutics

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of next-generation therapies for obesity and related conditions. Their mission is to empower people to transform their lives through innovative treatments that enhance overall health, backed by a commitment to scientific and clinical excellence.

Products & Services

KAI-9531 Injectable:A GLP-1/GIP receptor dual agonist formulated as an injectable peptide in clinical development for the treatment of obesity and type 2 diabetes.

Specialties

Obesity therapies GLP-1/GIP receptor agonists Oral and injectable peptide therapies Type 2 diabetes treatments Clinical-stage drug development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 600000000 MR: - FA: $600 million FAN: 600000000	D: 2025-10-14 FD: 2025-10-14	15 investors
2	RT: Series A T: - FT: Series A	A: 400000000 MR: - FA: $400 million FAN: 400000000	D: 2024-10-01 FD: 2024-10-01	4 investors

Series B Latest

2025-10-14

$600.0M

15 investors (Pro only)

Series A 2024-10-01

$400.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ron Renaud

President and Chief Executive Officer

LinkedIn (Pro only)

S

Scott Akamine

Chief Legal Officer

LinkedIn (Pro only)

D

Doug Bakan

Chief Technology Officer

LinkedIn (Pro only)

P

Paul Burgess

Chief Operating Officer and Chief Business Officer

P

Paula Cloghessy

Chief People Officer

J

Jamie Coleman

Chief Commercial Officer

View 21 more team members with Pro

Unlock Full Team Directory

Recent News